1. TransMedics will participate in two upcoming investor conferences. 2. Fireside chat at TD Cowen on March 3, 2025. 3. Presentation at Oppenheimer conference on March 17, 2025. 4. Live webcast available on TransMedics' investor website. 5. Company focuses on improving organ transplant therapy.
Company participation in key investor events may boost investor confidence, similar to past instances where conferences led to positive stock movement for healthcare companies.
Increased visibility and engagement at conferences can attract investor interest, directly impacting stock valuation and performance.
Upcoming conferences provide immediate visibility and may influence stock behavior shortly thereafter, akin to prior conference impacts on biotech stocks.
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston on Monday, March 3, 2025, at 11:50 a.m. EST and virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference on Monday, March 17, 2025, at 9:20 a.m. EST.
Event: TD Cowen 45th Annual Health Care Conference
Date: Monday, March 3, 2025
Time: 11:50 a.m. EST
Event: Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Date: Monday, March 17, 2025
Time: 9:20 a.m. EST
A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com
SOURCE TransMedics Group, Inc.